TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9825744
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 15 mg weekly i.m. injections for 1 year
Study: 9825744
Drug: Gold sodium
Normalized name: Gold Sodium Thiomalate
DrugBank: Gold (DB14154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold sodium thiomalate (GSTM) 50 mg weekly i.m. injections for 1 year
Study: 7854994
Drug: Loratadine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine (10 mg daily for 28 days)
Study: 809805
Drug: Low-dose EHDP
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose EHDP
Study: 29045535
Drug: selumetinib 75
Normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: selumetinib 75 mg b.i.d. plus docetaxel 60 mg/m2 (SEL+DOC 60)
Study: 29045535
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus docetaxel 75 mg/m2 (PBO+DOC 75)
Study: 20941455
Drug: Apixaban 2.5
Normalized name: apixaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 2.5 mg once daily
Study: 20941455
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 mg once‐daily or 30 mg twice‐daily)
Study: 17296165
Drug: Habituation Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Habituation Based Exposure Therapy (HBET)
Study: 7820960
Drug: CDP-choline (cytidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP-choline (cytidine diphosphate choline) administered daily for one week after a single intravenous injection.
Study: 24499168
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg + metformin
Study: 22540883
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + metformin
Study: 18496564
Drug: Efalizumab (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab (subcutaneous treatment for 12 weeks)
Study: 24223344
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) ketamine 0.5mg/kg
Study: 24223344
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) ketamine 0.5 mg/kg
Study: 20697700
Drug: Ritonavir 300
Normalized name: nirmatrelvir / ritonavir 300 MG /100 MG ; 150 MG / 100 MG Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir 300 mg b.i.d. for 4 days
Study: 20697700
Drug: Lopinavir/ritonavir 400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir 400/100 mg b.i.d. for 4 days
Study: 18441036
Drug: Robot-mediated therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-mediated therapy
Study: 18441036
Drug: Sling suspension
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sling suspension phase
Study: 12673669
Drug: Testim (1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testim (1% testosterone topical gel, 50 mg)
Study: 12673669
Drug: AndroGel (1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: AndroGel (1% testosterone topical gel, 50 mg)
Study: 8907096
Drug: Therapeutic treatments
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic treatments (3 brief treatments for depression)
Study: 27682852
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab (IVR) 0.25 mg
Study: 27682852
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB) 0.625 mg
Study: 25491116
Drug: 1% pimecrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% pimecrolimus cream
Study: 19541679
Drug: Dexmedetomidine 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 2 microg kg(‐1) in normal saline 1 ml
Study: 17478142
Drug: Nicorandil 12
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil 12 mg intravenously before PCI
Study: 15926604
Drug: COX-2 selective
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: COX-2 selective inhibitors
Study: 6357035
Drug: Both inpatient
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both inpatient and outpatient treatment
Study: 22055006
Drug: Single-injection PVB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection PVB (20 mL 0.5% bupivacaine with 1:200,000 epinephrine at T6, n = 25)
Study: 15091194
Drug: Alpha-tocopherol supplementation
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-tocopherol supplementation (1000 mg/day for 3 months)
Study: 12243810
Drug: q.d. RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: q.d. RT (60 Gy in 30 daily fractions) with etoposide and cisplatin (EP)
Study: 9828758
Drug: 0.75 g
Normalized name: Allantoin 0.75 g in 75 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 g fructose/kg body weight
Study: 9828758
Drug: 0.75 g
Normalized name: Allantoin 0.75 g in 75 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 g starch/kg body weight
Study: 7926574
Drug: Intracervical gel
Normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical gel containing 0.5 mg PgE2
Study: 7926574
Drug: Intravaginal tablet
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal tablet containing 3 mg PgE2
Study: 27017282
Drug: G-CSF 150
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF 150 µg/body/day
Study: 27017282
Drug: G-CSF 300
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF 300 µg/body/day
Study: 25693332
Drug: Sugammadex 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 4.0 mg . kg‐1
Study: 19204524
Drug: Problem drug
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem drug use
Study: 19204524
Drug: Professional treatment
Normalized name: ANHYDROUS DEXTROSE 5 g in 20 g / CURCUMIN 4 g in 20 g / ICOSAPENT 3 g in 20 g / CHOLECALCIFEROL 2 g in 20 g TOPICAL GEL [SOUTH MOON Propolis Professional Treatment Gel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional treatment for substance use
Study: 15000887
Drug: Propofol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.1 mg/kg/min) intravenously for anesthesia maintenance
Study: 15000887
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received fentanyl 10 microg/kg intravenously and inhaled enflurane (1 %‐1.5 %)
Study: 2522405
Drug: Low initial
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low initial dosage of acitretin (10, 30, 50 mg/day)
Study: 2522405
Drug: Constant dosage
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant dosage of acitretin (30 mg/day)
Study: 2522405
Drug: High initial
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High initial dosage of acitretin (50, 30, 10 mg/day)
Study: 2522405
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (10, 30, or 50 mg/day) during open phase
Study: 24906471
Drug: 5-methyltetrahydrofolate (5-MTHF)
Normalized name: 5-METHYLTETRAHYDROFOLIC ACID
DrugBank: 5-methyltetrahydrofolic acid (DB04789)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-methyltetrahydrofolate (5-MTHF) 15 mg/day for 3 weeks
Study: 23913405
Drug: Clopidogrel napadisilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel napadisilate 75 mg once daily
Study: 23913405
Drug: Clopidogrel bisulfate
Normalized name: Clopidogrel Bisulfate
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel bisulfate 75 mg once daily
Study: 21871589
Drug: Denosumab 0.03,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 0.03, 0.1, 0.3, 1.0 or 3.0 mg/kg
Study: 16439874
Drug: Therapeutic immunization
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic immunization with four boosts of ALVAC 1433 and HIV‐LIPO‐6T vaccines followed by three cycles of subcutaneous interleukin‐2
Study: 16439874
Drug: Antiretroviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral treatment alone (Control)
Study: 9411672
Drug: Postoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative treatment with 500 mg of 17‐1A antibody, followed by four 100 mg infusions each month.
Study: 2871538
Drug: Physiologic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic saline solutions
Study: 26222393
Drug: PDPH receiving
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDPH receiving a blood patch
Study: 19131059
Drug: Homeostasis model
Normalized name: CALCIUM HOMEOSTASIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeostasis model assessment of insulin resistance in women with PCOS
Study: 15668606
Drug: CEE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 mg/day + MPA 5 mg/day
Study: 9394855
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 40 mg q.i.d.
Study: 1674677
Drug: Metocurine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metocurine 0.1 mg.kg‐1 plus pancuronium 0.02 mg.kg‐1 (M-P)
Study: 31023525
Drug: Reduction of
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction of daily sugar intake to less than 25 g
Study: 21188440
Drug: Midazolam and
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam and Diclofenac (0.05 mg/kg midazolam and 1.5 mg/kg diclofenac, 15 min before surgical incision)
Study: 21188440
Drug: Diclofenac (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (1.5 mg/kg diclofenac, 15 min before surgical incision)
Study: 9659700
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg Dinoprostongel (Prepidil)
Study: 9659700
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg Gemeprost vaginal suppositories (Cergem)
Study: 9659700
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg Dinoprostongel (repeated applications)
Study: 9659700
Drug: Repeated therapy
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated therapy with Gemeprost
Study: 7697843
Drug: 90-micrograms/kg bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90-micrograms/kg bolus of Integrelin followed by a 1.0-micrograms.kg-1.min-1 infusion for 4 hours
Study: 7697843
Drug: 90-micrograms/kg bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90-micrograms/kg bolus of Integrelin followed by a 1.0-micrograms.kg-1.min-1 infusion for 12 hours
Study: 23315286
Drug: 0.1 l/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 l/min 100% oxygen
Study: 23315286
Drug: 0.1 l/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 l/min air (21% oxygen)
Study: 23315286
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (tubing disconnected from flow-meter)
Study: 26688733
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg twice daily
Study: 29282768
Drug: Placebo transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo transdermal patches
Study: 29554173
Drug: Vaginal 10-μg
Normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal 10-μg estradiol tablet
Study: 19912212
Drug: Degarelix subcutaneous
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Degarelix subcutaneous 240 mg for 1 month followed by monthly maintenance doses of 80 mg or 160 mg
Study: 19962227
Drug: Leuprolide 7.5
Normalized name: leuprolide 7.5 mg/month intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide 7.5 mg/month
Study: 1621239
Drug: MF 701,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF 701, 300 mg IM b.i.d. (second phase)
Study: 18534218
Drug: Low-dose indomethacin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose indomethacin (0.1 mg/kg/d)
Study: 18534218
Drug: Higher-dose indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher-dose indomethacin (0.2 or 0.5 mg/kg/d)
Study: 15755044
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (leuprolide acetate)
Study: 14557467
Drug: oral glucose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral glucose, iv octreotide
Study: 14557467
Drug: oral glucose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral glucose, iv saline
Study: 11050700
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release chitosan formulation of pentoxifylline
Study: 6139745
Drug: Steroids and
Normalized name: Corticosteroids and mydriatics in combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids and sulfasalazine (group A)
Study: 6139745
Drug: Elementary diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elementary diet with steroids and sulfasalazine (group C)
Study: 22902096
Drug: Bezafibrate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (400 mg daily)
Study: 10710049
Drug: Oral (p.o.)
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral (p.o.) pantoprazole (40 mg and 20 mg)
Study: 8452191
Drug: Fleroxacin 400
Normalized name: fleroxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 400 mg
Study: 1485530
Drug: Raclopride 2‐8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raclopride 2‐8 mg twice daily
Study: 1485530
Drug: Haloperidol 5‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 5‐20 mg twice daily
Study: 28507219
Drug: Subcutaneous golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous golimumab (30 mg/m2 of body surface area; maximum: 50 mg/dose) every 4 weeks with weekly methotrexate
Study: 15978098
Drug: Epsilon aminocaproic
Normalized name: Epsilon Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epsilon aminocaproic acid (EACA) (10 g over 30 min followed by 5 g over 3 h)
Study: 12679467
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human FSH (r‐hFSH) at doses of 0, 37.5, 75, or 150 IU
Study: 12679467
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human FSH (r‐hFSH) at doses of 37.5 IU and 75 IU
Study: 31523919
Drug: Fractional CO2
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO2 laser treatment (power 12 W, time on 3 ms, PPI 5), two sessions four weeks apart
Study: 31523919
Drug: Topical keratolytic
Normalized name: KERATOLYTICS/CAUSTICS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical keratolytic (10% urea)
Study: 20120420
Drug: Fractional CO2
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO2 laser treatment
Study: 23859414
Drug: Sauna treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sauna treatment (30 minutes, 3 days per week for 6 weeks)
Study: 9679792
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg/d)
Study: 12115946
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide (CP; n = 12)
Study: 25939797
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 4 weeks
Study: 2299367
Drug: Empiric antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric antimicrobial therapy (ET)
Study: 2299367
Drug: Complication rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Complication rate comparison between patients receiving only empiric antibiotics and all patients having an OLB
Study: 24046309
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg oseltamivir twice daily for 5 days
Study: 24046309
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg oseltamivir (subanalysis for influenza B)
Study: 24046309
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg oseltamivir (subanalysis for influenza B)
Study: 11700183
Drug: Vaccine (180,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine (180, 360, and 540 microg doses)
Study: 8273795
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g amoxicillin tid intravenously (n = 15)
Study: 15946144
Drug: rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 10 mg, amoxicillin 1000 mg and metronidazole 400 mg (RAM-10)
Study: 10078677
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg acetaminophen orally (placebo)
Study: 8652038
Drug: Clorazepate dipotassium
Normalized name: Clorazepate Dipotassium
DrugBank: Clorazepic acid (DB00628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorazepate dipotassium (10 mg for < 55 kg; 20 mg for > 55 kg)
Study: 8652038
Drug: Nordiazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nordiazepam (1 gtt/kg; 5 mg = 24 gtt)
Study: 6444862
Drug: Actinac (lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actinac (lotion with chloramphenicol)
Study: 6444862
Drug: Formulation without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation without chloramphenicol
Study: 26083828
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (recombinant hepatitis B)
Study: 20002013
Drug: Rapid enteral
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid enteral feeding advancement at 30 mL/kg/day
Study: 16183794
Drug: Oral magnesium-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral magnesium-containing drugs
Study: 16183794
Drug: Not applicable
Normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable (control group without magnesium drugs)
Study: 14581795
Drug: Standard parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard parenteral nutrition (n = 18)
Study: 25972515
Drug: Daikenchuto (15.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daikenchuto (15.0 g/day, t.i.d)
Study: 16124431
Drug: Ivermectin, single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin, single dose of 50, 100, 150, or 200 microg/kg bodyweight
Study: 16124431
Drug: Albendazole, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole, 400 mg twice a day for 14 days
Study: 10480630
Drug: Thalidomide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (200 mg/day for 4 weeks)
Study: 8916820
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg in 10 ml 0.9% saline
Study: 2064488
Drug: Intermittent intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent intravenous (IV) injections of morphine sulfate 4 mg every 30 to 60 minutes (phase 1)
Study: 2064488
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (PCA) with morphine sulfate 2 mg bolus then 1.0 mg with a 6-minute lockout (phase 1)
Study: 6698443
Drug: High sugar
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sugar diet (112 g refined sucrose)
Study: 31256656
Drug: Fructosamine >
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructosamine > 293 µmol/l
Study: 9220304
Drug: Standard Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Cognitive Therapy (SCT)
Study: 9220304
Drug: Focused Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused Cognitive Therapy (FCT)
Study: 8192475
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of vancomycin per kg of body weight before anesthesia
Study: 8192475
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of vancomycin per kg of body weight before anesthesia and a second 7.5‐mg/kg dose at the time of initiation of cardiopulmonary bypass
Study: 3791247
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg AZQ/m2/day, i.v., for 3 consecutive days, every 4 weeks
Study: 3791247
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg BCNU/m2, i.v., every 8 weeks
Study: 28831250
Drug: Regular medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular medical treatment (Control)
Study: 20542963
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) prednisone
Study: 8456144
Drug: Flexibility training
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexibility training (n = 9): performed postural control exercises weekly
Study: 31167863
Drug: ICAN QUIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICAN QUIT in Pregnancy intervention (three 1-hour webinar sessions, educational resource package, and free oral NRT)
Study: 27310332
Drug: CTP-499 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTP-499 (600 mg orally once daily for 2 weeks, then twice daily for 2 additional weeks)
Study: 20923244
Drug: Sitagliptin 50
Normalized name: SITagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 50 mg and metformin 500 mg co-administration
Study: 20923244
Drug: Sitagliptin/metformin 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin/metformin 50 mg/1000 mg FDC tablet